Table 1 Demographics and baseline characteristics of patients in the study population
Characteristic | Statin + CoA (n = 152) | Statin + Placebo (n = 152) |
|---|---|---|
Age, years | 54.8 ± 12.1 | 53.1 ± 13.1 |
Sex, n (%) | Â | Â |
  Male | 81 (53.3) | 87 (57.2) |
  Female | 71 (46.7) | 65 (42.8) |
BMI, kg/m2 | Â | Â |
  Male | 26.3 ± 2.8 | 25.5 ± 2.4 |
  Female | 24.7 ± 2.9 | 24.1 ± 2.8 |
SBP, mmHg | 131.4 ± 12.4 | 128.5 ± 13.9 |
DBP, mmHg | 80.4 ± 9.1 | 78.1 ± 8.9 |
Risk factors, n (%) | Â | Â |
  Type 2 DM | 23 (15.1) | 28 (18.4) |
  Hypertension | 62 (40.8) | 49 (32.2) |
  Coronary artery disease | 18 (11.8) | 15 (9.9) |
  Stroke | 3 (2.0) | 0 (0) |
Medications, n (%) | Â | Â |
  ACEIs/ARBs | 38 (25.0) | 27 (17.8) |
  β-blockers | 32 (21.1) | 20 (13.2) |
  Calcium channel blockers | 40 (26.3) | 24 (15.8) |
  Diuretics | 7 (4.6) | 1 (0.7) |
  Insulin | 5 (3.3) | 4 (2.6) |
  Oral hypoglycemic agents | 28 (18.4) | 26 (17.1) |
  Platelet aggregation inhibitors | 25 (16.4) | 18 (11.8) |
  Organic nitrates | 2 (1.3) | 3 (2.0) |
Statins | Â | Â |
  Atorvastatin | 96 (63.2) | 94 (61.8) |
  Rosuvastatin | 12 (7.9) | 15 (9.9) |
  Simvastatin | 29 (19.1) | 34 (22.4) |
  Fluvastatin | 14 (9.2) | 9 (5.9) |
  Lovastatin | 1 (0.7) | 0 (0.0) |